why choose us

First received: April 08, 2025

Clinical Trial: Clinical Trial to Evaluate the Tolerance of TQB2210 Injection

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Advanced Malignant Tumours

Study Type: INTERVENTIONAL


Official Title: Phase I Clinical Trial Evaluating the Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB2210 Injection in Subjects With Advanced Malignant Tumors

Brief Summary: TQB2210 injection is a humanized monoclonal antibody against FGFR2b, which can bind to FGFR2b with high specificity and inhibit tumor growth by blocking the signaling pathway mediated by fibroblast growth factor receptor.The aim of this experiment is to evaluate the tolerability, pharmacokinetics, and preliminary efficacy of TQB2210 injection in patients with advanced malignant tumors, and to assess its effectiveness and phase II recommended dose (RP2D) in advanced malignant tumors with FGFR2b overexpression, such…

Read more